GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
72.92
-2.67 (-3.53%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close75.59
Open75.41
Bid72.76 x 34100
Ask72.93 x 1000
Day's Range72.06 - 75.54
52 Week Range64.27 - 89.54
Volume13,338,302
Avg. Volume6,788,803
Market Cap94.529B
Beta1.45
PE Ratio (TTM)43.56
EPS (TTM)1.67
Earnings DateOct 24, 2018 - Oct 29, 2018
Forward Dividend & Yield2.28 (2.93%)
Ex-Dividend Date2018-09-13
1y Target Est87.87
Trade prices are not sourced from all markets
  • Stanley Druckenmiller Bets on Facebook and Oil
    GuruFocus.comyesterday

    Stanley Druckenmiller Bets on Facebook and Oil

    Stanley Druckenmiller (Trades, Portfolio)'s Duquesne Capital spent purchased 19 new stocks in the second quarter, with his biggest purchase being of Facebook (FB), he revealed Wednesday. Warning! GuruFocus has detected 5 Warning Signs with SPLK.

  • Biogen Expected to Report Robust Rise in Diluted EPS in 2018
    Market Realistyesterday

    Biogen Expected to Report Robust Rise in Diluted EPS in 2018

    In its Q2 2018 earnings conference call, Biogen (BIIB) updated its 2018 GAAP EPS guidance from the previously projected range of $22.20–$23.20 to $21.80–$22.40, which implies a YoY (year-over-year) rise of 83%–87%.

  • Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?
    Zacksyesterday

    Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year?

    Is (GILD) Outperforming Other Medical Stocks This Year?

  • Considering Allergan’s Q2 2018 Revenue Trend
    Market Realistyesterday

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

  • Analyst Recommendations for Biogen and Its Peers in August
    Market Realistyesterday

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401, an investigational anti-amyloid-beta (or Aβ) protofibril antibody, in early Alzheimer’s disease (or AD) indication after 18 months of therapy. The patients also included those suffering from AD-related mild cognitive impairment as well as those with mild AD. The results from the Phase 2 trial seem to validate beta-amyloid as a potential target for treating Alzheimer’s disease.

  • Why Vertex Is Expected to Report Robust EPS Growth in 2018
    Market Realist2 days ago

    Why Vertex Is Expected to Report Robust EPS Growth in 2018

    How Is Vertex Pharmaceuticals Positioned in August? In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) reiterated its projection for non-GAAP combined selling, general, and administrative (or SG&A) and research and development (or R&D) expenses to come in in the range of $1.5 billion and $1.55 billion for fiscal 2018. In Q2 2018, the company reported non-GAAP combined R&D and SG&A expenses close to $388 million.

  • Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth
    Market Realist2 days ago

    Vertex Pharmaceuticals Is Expected to See Robust Revenue Growth

    In its Q2 2018 earnings conference call, Vertex Pharmaceuticals (VRTX) updated its revenue guidance for fiscal 2018 from the previously projected range of $2.65 billion–$2.8 billion to $2.9 billion–$3.0 billion. The midpoint of this guidance range would imply a 36% year-over-year (or YoY) rise in revenues in fiscal 2018. This expectation has mainly been driven by the solid adoption of Symdeko since its launch in US markets. The company has not assumed the impact of securing new reimbursement for its CF drugs in markets outside the US in its fiscal 2018 revenue guidance.

  • Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children
    Zacks2 days ago

    Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

    Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

  • Should Gilead Be Worried About This New Monthly HIV Medication?
    Motley Fool2 days ago

    Should Gilead Be Worried About This New Monthly HIV Medication?

    The devil is in the undisclosed details.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters3 days ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Long-acting injection a shot in the arm for GSK's HIV business
    Reuters3 days ago

    Long-acting injection a shot in the arm for GSK's HIV business

    A long-acting injection developed by GlaxoSmithKline and given once a month has proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker's key HIV business. GSK's majority-owned ViiV Healthcare unit said on Wednesday the experimental two-drug injection of cabotegravir and rilpivirine maintained similar rates of viral suppression compared with a standard three-drug oral regimen, after 48 weeks of a clinical trial. GSK hopes its new approach will allow it to compete more effectively against Gilead Sciences, the U.S. drugmaker that dominates the $26 billion-a-year HIV market.

  • Reuters4 days ago

    Congo deploys experimental Ebola treatment as cases rise

    GOMA, Democratic Republic of Congo/GENEVA, Aug 14 (Reuters) - D emocratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak. Forty-two people are believed to have died from the haemorrhagic fever in Congo's tenth Ebola outbreak since it was discovered in the 1970s. In all, there have been 66 cases to date, including 39 confirmed and 27 probable, the health ministry said on Tuesday evening, an increase of nine confirmed cases since Monday.

  • After five months on job, Gilead chief medical officer joins exodus
    American City Business Journals4 days ago

    After five months on job, Gilead chief medical officer joins exodus

    Dr. Andrew Cheng, appointed in March as chief medical officer of Gilead Sciences Inc., is leaving the company, joining an exodus of top-level executives from the Foster City-based drug developer. Cheng will "pursue another opportunity," Gilead (NASDAQ: GILD) said Tuesday while disclosing two promotions. Dr. Diana Brainard was promoted from vice president of clinical research, to senior vice president of HIV and emerging viral infections, and Gregg Alton, executive vice president of corporate and medical affairs, will become Gilead's first chief patient officer.

  • Business Wire4 days ago

    Gilead Sciences Announces Executive Promotions

    Gilead Sciences, Inc. (GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients. The company also announced that Diana Brainard, MD, has been promoted to Senior Vice President, HIV and Emerging Viral Infections, and that Andrew Cheng, MD, PhD, Chief Medical Officer, has decided to leave Gilead to pursue another opportunity.

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacks5 days ago

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zacks5 days ago

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • Biotech ETFs in Focus on String of Q2 Earnings Beat
    Zacks8 days ago

    Biotech ETFs in Focus on String of Q2 Earnings Beat

    Biotech ETFs draw attention post impressive Q2 results.

  • Investopedia8 days ago

    Gilead Sciences Seen Rising 13% on Better Outlook

    Gilead Sciences Inc. ( GILD) has risen by more than 18% since the start of May, and it looks likes shares may still be heading even higher. Analysts have been upping their earnings and revenue outlook for the biotech company since it reported blowout second-quarter results at the end of July, and now see the stock rising by nearly 13% based on the average price targets. Analysts have increased their average price on the stock to $87.40 since the company reported results, up from a prior target of $85.84.

  • InvestorPlace8 days ago

    You Better Be Careful with Merck Stock, Especially at These Highs

    Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.

  • Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
    Zacks8 days ago

    Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat

    Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.

  • Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses
    Market Realist9 days ago

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.

  • BeiGene’s Q2 2018 Earnings: Reports Revenue Growth
    Market Realist9 days ago

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its second-quarter earnings on August 9. The company surpassed Wall Street analysts’ estimates for revenues but missed its EPS estimates. BeiGene reported adjusted EPS of -$2.92 on revenues of $52.8 million, compared to its estimated EPS of -$2.06 on revenues of $22.5 million. The chart below compares BeiGene’s revenues and EPS since the first quarter of 2017.

  • Here’s How Exelixis Is Financially Positioned Now
    Market Realist9 days ago

    Here’s How Exelixis Is Financially Positioned Now

    Exelixis (EXEL) generated net revenues of $186.1 million in the second quarter of 2018 compared to $99 million in the second quarter of 2017. In the first half of 2018, Exelixis reported revenues of $399.8 million compared to $179.9 million in the first half of 2017. In the first half of 2018, Exelixis generated revenues of $280.1 million, reflecting ~92% YoY (year-over-year) growth.

  • PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
    Zacks9 days ago

    PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

    PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

  • Is Crispr Therapeutics Stock Grossly Overvalued?
    Motley Fool9 days ago

    Is Crispr Therapeutics Stock Grossly Overvalued?

    Crispr's stock has started to lose momentum after blasting higher earlier this year. Is the market correcting a prior mistake, or is this dip a buying opportunity?